Nom du produit:Methyl 3-oxotetrahydrothiophene-2-carboxylate

IUPAC Name:methyl 3-oxothiolane-2-carboxylate

CAS:2689-69-2
Formule moléculaire:C6H8O3S
Pureté:97%
Numéro de catalogue:CM199155
Poids moléculaire:160.19

Unité d'emballage Stock disponible Prix($) Quantité
CM199155-1g in stock ƿƿ
CM199155-5g in stock ŤƚǪ
CM199155-10g in stock ǙŮľ

Pour une utilisation en R&D uniquement..

Formulaire de demande

   refresh    

Détails du produit

N° CAS:2689-69-2
Formule moléculaire:C6H8O3S
Point de fusion:-
Code SMILES:COC(=O)C1SCCC1=O
Densité:
Numéro de catalogue:CM199155
Poids moléculaire:160.19
Point d'ébullition:248.4°C at 760 mmHg
N° Mdl:MFCD00156156
Stockage:Keep in dark place, store at 2-8°C.

Category Infos

Tetrahydrothiophenes
Tetrahydrothiophene is a sulfur-containing saturated heterocyclic compound obtained by catalytic hydrogenation of thiophene. After thiophene is reduced to tetrahydrothiophene, it no longer has a conjugated system and aromaticity. Therefore, tetrahydrothiophene shows the properties of general thioethers. Easily oxidized to sulfoxides and sulfones. Tetrahydrothiophene can be used as a raw material for the production of pharmaceuticals, pesticides and photochemicals.

Column Infos

Nerandomilast
Boehringer’s nerandomilast meets primary endpoint in pivotal phase-III FIBRONEER™-IPF study.
Nerandomilast (BI 1015550) is an investigational oral, preferential inhibitor of phosphodiesterase 4B (PDE4B) that is being studied as a potential treatment for idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF). This compound is an investigational agent and has not been approved for use. Nerandomilast was granted FDA Breakthrough Therapy Designation for the treatment of IPF in February 2022.